相关实验视频
Updated: May 13, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
艾尔粉样化症:当前的治疗和结果
1Department of Cancer, Northwell Health Cancer Institute & Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, New York, USA.
轻链 Amyloidosis (AL) 是一种通过活检诊断的全身性疾病. 目前的一线治疗包括DaraCyborD,以及新兴疗法,如venetoclax和CAR T细胞疗法,用于复发病例.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 轻链氨基粉症 (AL) 是一种全身性疾病,其特征是氨基状纤维的沉积.
- 由于非特异性症状,诊断往往会延迟,需要组织活检确认.
- 风险分层包括评估器官参与和细胞遗传特征.
研究的目的:
- 审查AL粉样化症诊断和治疗的当前情况.
- 突出确立的第一线治疗方法和复发/耐药性疾病的新兴选择.
- 为提供AL粉样性粉症正在进行的临床试验的概述.
主要方法:
- 对诊断标准和风险分层方法的文献综述.
- 目前FDA批准的第一线疗法 (DaraCyborD) 的摘要.
- 包括venetoclax和CAR T细胞疗法 (向BCMA) 在内的试验性治疗方法的概述,用于复发性/耐药AL粉样化症.
主要成果:
- 组织活检对于诊断AL氨基粉症至关重要.
- 达拉图穆马布,环胺,博尔特佐米布和德克萨米他 (DaraCyborD) 是FDA批准的唯一一线治疗方案.
- 威尼托克拉克斯和CAR T细胞疗法在复发/耐药环境中表现有前途,特别是对于特定的遗传特征 (例如,t(11;14)).
结论:
- 早期诊断和风险分层对于管理AL粉样性粉症至关重要.
- DaraCyborD提供了一种标准的第一线治疗方法.
- 研究性疗法正在扩大复发或耐药疾病患者的治疗选择,为患者提供新的希望.
更多相关视频
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Chronic Pancreatitis II: Collaborative Care
Assessment: